1. Safety and efficacy of repeated-dose intravenous ketamine for treatment-resistant depression;aan het Rot;Biol. Psychiatry,2010
2. Serotonin and hallucinogens;Aghajanian;Neuropsychopharmacol. Official Publ. Am. Coll. Neuropsychopharmacol.,1999
3. Serotonin–Glutamate interactions: a new target for antipsychotic drugs;Aghajanian;Neuropsychopharmacology,1999
4. Allergan Announces Phase 3 Results for Rapastinel as an Adjunctive Treatment of Major Depressive Disorder (MDD). (n.d.). Retrieved July28, 2019, fromhttps://www.prnewswire.com/news-releases/allergan-announces-phase-3-results-for-rapastinel-as-an-adjunctive-treatment-of-major-depressive-disorder-mdd-300808044.html.
5. Anxiety during ketamine infusions is associated with negative treatment responses in major depressive disorder;Aust;European Neuropsychopharmacology: The Journal of the European College of Neuropsychopharmacology,2019